Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Galectin-1 for neuroprotection?
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients.
Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Function and distribution of three types of rectifying channel in rat spinal root myelinated axons.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
The potential role of epigenetic modifications in the heritability of multiple sclerosis.

Pages